thecardiologyadvisor.com
Cure8 news brief
Why This Matters
People with IBD who need advanced therapies may worry about cardiovascular risks linked to some JAK inhibitors. This study suggests, in a real-world cohort with cardiovascular risk factors, short-term (1-year) MACE risk was similar for JAK vs TNF inhibitors, but longer follow-up is needed.
Who Should Pay Attention
Adult patients with IBD (Crohn’s disease or ulcerative colitis) who have cardiovascular risk factors, clinicians prescribing JAK or TNF inhibitors, and researchers studying IBD drug safety.
Study Snapshot
Story typeResearch news
Evidence typeConference abstract
Source depthFull source text
What To Know
This analysis used TriNetX data and propensity-score matching in patients aged ≥50 with ulcerative colitis or Crohn’s disease who had at least one cardiovascular risk factor. The most common JAK agent reported in the cohort was upadacitinib.
After matching, rates of MACE and secondary outcomes (stroke, myocardial infarction, heart failure, malignancy, all-cause mortality, venous thromboembolism) did not differ significantly between groups. The investigators recommended continued monitoring and prospective long-term studies to better define cardiovascular safety in high-risk populations.
Key limitations and tone: This report summarizes a conference abstract and retrospective database analysis; it is not a randomized trial. The findings are preliminary and described by the investigators as requiring longer prospective study for definitive conclusions.
Keep In Mind
Results come from a retrospective, propensity-matched analysis using electronic-health-record data presented as an abstract at a conference (AIBD 2024). Such studies can help signal safety patterns but cannot prove causation; randomized or long-term prospective studies are needed to confirm cardiovascular safety.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationthecardiologyadvisor.com
Indexed viaBing News
Source typeResearch news
PublishedFeb 10, 2025, 6:18 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ustekinumab Has Better Cardiovascular Safety Than Vedolizumab in IBD Management
Older adults with IBD have higher cardiovascular risk; medication choice may affect cardiovascular outcomes. This study suggests ustekinumab users had fewer deaths and some cardiac events than vedolizumab users, which...
DDW: Combination therapy shows efficacy for Crohn disease, ulcerative colitis
Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
No new safety risks for upadacitinib in IBD at 3 years; uptick in herpes zoster in Crohn’s
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.